Receptor for Advanced Glycation End Products in Donor Lungs is Associated with Primary Graft Dysfunction After Lung Transplantation

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2010 Feb 4

PMID 20121754

Citations 23

Authors

A Pelaez

S D Force

A A Gal

D C Neujahr

A M Ramirez

P M Naik

D A Quintero

A V Pileggi

K A Easley

R Echeverry

E C Lawrence

D M Guidot

P O Mitchell

Affiliations

Soon will be listed here.

Abstract

Development of primary graft dysfunction (PGD) is associated with poor outcomes after transplantation. We hypothesized that Receptor for Advanced Glycation End-products (RAGE) levels in donor lungs is associated with the development of PGD. Furthermore, we hypothesized that RAGE levels would be increased with PGD in recipients after transplantation. We measured RAGE in bronchoalveolar lavage fluid (BALf) from 25 donors and 34 recipients. RAGE was also detected in biopsies (transbronchial biopsy) from recipients with and without PGD. RAGE levels were significantly higher in donor lungs that subsequently developed sustained PGD versus transplanted lungs that did not display PGD. Donor RAGE level was a predictor of recipient PGD (odds ratio = 1.768 per 0.25 ng/mL increase in donor RAGE level). In addition, RAGE levels remained high for 14 days in those recipients that developed severe graft dysfunction. Recipients may be at higher risk for developing PGD if they receive transplanted organs that have higher levels of soluble RAGE prior to explantation. Moreover, the clinical and pathologic abnormalities associated with PGD posttransplantation are associated with increased RAGE expression. These findings also raise the possibility that targeting the RAGE signaling pathway could be a novel strategy for treatment and/or prevention of PGD.

Citing Articles

Proteomic Analysis of Primary Graft Dysfunction in Porcine Lung Transplantation Reveals Alveolar-Capillary Barrier Changes Underlying the High Particle Flow Rate in Exhaled Breath.

Niroomand A, Hirdman G, Bechet N, Ghaidan H, Stenlo M, Kjellstrom S Transpl Int. 2024; 37:12298.

PMID: 38741700 PMC: 11089893. DOI: 10.3389/ti.2024.12298.

Incidence of primary graft dysfunction is higher according to the new ISHLT 2016 guidelines and correlates with clinical and molecular risk factors.

Daoud D, Chacon Alberty L, Wei Q, Hochman Mendez C, Virk M, Mase J J Thorac Dis. 2021; 13(6):3426-3442.

PMID: 34277039 PMC: 8264697. DOI: 10.21037/jtd-20-3564.

The role of innate immunity in the long-term outcome of lung transplantation.

Kawashima M, Juvet S Ann Transl Med. 2020; 8(6):412.

PMID: 32355856 PMC: 7186608. DOI: 10.21037/atm.2020.03.20.

Long non-coding RNA X-inactive specific transcript silencing ameliorates primary graft dysfunction following lung transplantation through microRNA-21-dependent mechanism.

Li J, Wei L, Han Z, Chen Z, Zhang Q EBioMedicine. 2020; 52:102600.

PMID: 31981974 PMC: 6976928. DOI: 10.1016/j.ebiom.2019.102600.

Sequential broncho-alveolar lavages reflect distinct pulmonary compartments: clinical and research implications in lung transplantation.

Levy L, Juvet S, Boonstra K, Singer L, Azad S, Joe B Respir Res. 2018; 19(1):102.

PMID: 29801490 PMC: 5970521. DOI: 10.1186/s12931-018-0786-z.

References

Naik P, Marshall Lyon 3rd G, Ramirez A, Lawrence E, Neujahr D, Force S . Dapsone-induced hemolytic anemia in lung allograft recipients. J Heart Lung Transplant. 2008; 27(11):1198-202. DOI: 10.1016/j.healun.2008.07.025. View

Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, Makita K . Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells. 2004; 9(2):165-74. DOI: 10.1111/j.1356-9597.2004.00712.x. View

He M, Kubo H, Ishizawa K, Hegab A, Yamamoto Y, Yamamoto H . The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007; 293(6):L1427-36. DOI: 10.1152/ajplung.00075.2007. View

Calfee C, Budev M, Matthay M, Church G, Brady S, Uchida T . Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant. 2007; 26(7):675-80. PMC: 2741136. DOI: 10.1016/j.healun.2007.04.002. View

Briot R, Frank J, Uchida T, Lee J, Calfee C, Matthay M . Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. Chest. 2008; 135(2):269-275. PMC: 2714162. DOI: 10.1378/chest.08-0919. View

Ware L, Wang Y, Fang X, Warnock M, Sakuma T, Hall T . Assessment of lungs rejected for transplantation and implications for donor selection. Lancet. 2002; 360(9333):619-20. DOI: 10.1016/s0140-6736(02)09774-x. View

Calfee C, Ware L, Eisner M, Parsons P, Thompson B, Wickersham N . Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax. 2008; 63(12):1083-9. PMC: 2764528. DOI: 10.1136/thx.2008.095588. View

Christie J, Carby M, Bag R, Corris P, Hertz M, Weill D . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005; 24(10):1454-9. DOI: 10.1016/j.healun.2004.11.049. View

Ware L, Golden J, Finkbeiner W, Matthay M . Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation. Am J Respir Crit Care Med. 1999; 159(3):980-8. DOI: 10.1164/ajrccm.159.3.9802105. View

10.

Ware L, Matthay M . Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001; 163(6):1376-83. DOI: 10.1164/ajrccm.163.6.2004035. View

11.

Griffiths M, McAuley D . RAGE: a biomarker for acute lung injury. Thorax. 2008; 63(12):1034-6. DOI: 10.1136/thx.2008.101493. View

12.

Kaneda H, Waddell T, de Perrot M, Bai X, Gutierrez C, Arenovich T . Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant. 2006; 6(3):544-51. DOI: 10.1111/j.1600-6143.2005.01204.x. View

13.

Katsuoka F, Kawakami Y, Arai T, Imuta H, Fujiwara M, Kanma H . Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. Biochem Biophys Res Commun. 1997; 238(2):512-6. DOI: 10.1006/bbrc.1997.7263. View

14.

Christie J, Kotloff R, Ahya V, Tino G, Pochettino A, Gaughan C . The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med. 2005; 171(11):1312-6. PMC: 2718464. DOI: 10.1164/rccm.200409-1243OC. View

15.

Pelaez A, Lyon G, Force S, Ramirez A, Neujahr D, Foster M . Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009; 28(1):67-71. PMC: 3395057. DOI: 10.1016/j.healun.2008.10.008. View

16.

Sternberg D, Gowda R, Mehra D, Qu W, Weinberg A, Twaddell W . Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice. J Thorac Cardiovasc Surg. 2008; 136(6):1576-85. DOI: 10.1016/j.jtcvs.2008.05.032. View

17.

Burton C, Iversen M, Milman N, Zemtsovski M, Carlsen J, Steinbruchel D . Outcome of lung transplanted patients with primary graft dysfunction. Eur J Cardiothorac Surg. 2006; 31(1):75-82. DOI: 10.1016/j.ejcts.2006.10.024. View

18.

Arcasoy S, Fisher A, Hachem R, Scavuzzo M, Ware L . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant. 2005; 24(10):1483-8. DOI: 10.1016/j.healun.2004.11.314. View

19.

Anraku M, Cameron M, Waddell T, Liu M, Arenovich T, Sato M . Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant. 2008; 8(10):2140-8. DOI: 10.1111/j.1600-6143.2008.02354.x. View

20.

Krenn K, Klepetko W, Taghavi S, Paulus P, Aharinejad S . Vascular endothelial growth factor increases pulmonary vascular permeability in cystic fibrosis patients undergoing lung transplantation. Eur J Cardiothorac Surg. 2007; 32(1):35-41. DOI: 10.1016/j.ejcts.2007.04.006. View